INTI — Inhibitor Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.62m
- $0.93m
- 34
- 16
- 31
- 17
Annual cashflow statement for Inhibitor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.73 | -1.06 | -0.299 | 12.1 | -3.03 |
| Non-Cash Items | 0.27 | 0.229 | -0.004 | -0.508 | 0.014 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.242 | 0.004 | 0.082 | 0.142 | 0.312 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Cash from Operating Activities | -2.71 | -0.825 | -0.22 | 11.7 | -2.7 |
| Financing Cash Flow Items | 2.5 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.4 | 0.097 | 0.176 | 0.18 | -0.411 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.305 | -0.729 | -0.044 | 11.9 | -3.11 |